Critically evaluate the trade-off between rural access to medicines and pharmaceutical safety in light of the 2025 amendment to Schedule K of the Drugs Rules, 1945.

Q. Critically evaluate the trade-off between rural access to medicines and pharmaceutical safety in light of the 2025 amendment to Schedule K of the Drugs Rules, 1945. (15 marks, 250-350 words)

Schedule K of the Drugs Rules, 1945 exempts specified drug classes from licensing provisions of the Drugs and Cosmetics Act, 1940. By omitting the word "Syrup" from Entry 13, the Health Ministry's 2025 amendment ended the sale of cough syrups in villages of population below 1,000 without a retail licence [1]. The move rightly prioritises safety, but its access costs demand mitigation.

The case for tightening: safety imperatives - Paediatric deaths in Madhya Pradesh and Rajasthan were traced to diethylene glycol (DEG) contamination in Coldrif, Respifresh TR and ReLife — an industrial solvent causing acute kidney injury [2]. - WHO Medical Product Alert N°5/2025 (13 October 2025) globally flagged these Indian-made oral liquids, threatening India's standing as "pharmacy of the Global South" [2]. - The exemption had become a regulatory blind spot, allowing unlicensed grocery and general stores to dispense formulations no pharmacist ever screened. - It advances the right to health under Article 21 and the State's duty under Article 47 to improve public health.

The case for caution: access costs - India has lakhs of small villages; withdrawing OTC availability without expanding licensed outlets risks delayed treatment and recourse to quacks. - Contamination originates in manufacturing — use of industrial-grade glycerin, a Schedule M/GMP failure — so restricting the retail end treats the symptom, not the cause [2]. - Enforcement rests with state drug controllers, whose risk-based inspection capacity remains stretched despite hundreds of units inspected and actions taken [3]. - Regulation is a Concurrent List subject (Entry 19, List III), making uniform last-mile compliance difficult.

Access and safety are not genuine opposites: an unsafe medicine is not access. The amendment is therefore a necessary but partial correction — it must be paired with mandatory excipient testing, strict Schedule M enforcement, strengthened CDSCO–state coordination, and rapid expansion of Jan Aushadhi Kendras into small villages, so that regulatory rigour and rural reach advance together.

(~330 words)

Sources: 1. Union Ministry of Health and Family Welfare Amends Drugs Rules, 1945; Exemption for Sale of Cough Syrups in Small Villages Withdrawn (PIB) — omission of "Syrup" from Schedule K Entry 13; village population threshold below 1,000 2. Medical Product Alert N°5/2025: Substandard (contaminated) oral liquid medicines (WHO, 13 October 2025) — DEG contamination, implicated products, child deaths, health effects 3. Steps taken to Prevent Sale of Adulterated Drugs (PIB) — risk-based inspections by CDSCO with state regulators and enforcement actions